NeuralBase Submits HeartEase App for Google Play Store Review
MWN-AI** Summary
On August 12, 2025, NeuralBase AI Ltd. (OTC: NBBI) announced the submission of its HeartEase mobile application for review on the Google Play Store, marking a significant advancement in the company's mission to deliver AI-driven health and wellness support solutions. HeartEase is designed to provide users with real-time insights and personalized guidance focused on heart health, aiming to enhance wellness through technology. Following its anticipated launch on Android, NeuralBase plans to expedite the final testing phase of an iOS version, ensuring a wider reach for the app among mobile users globally.
CEO Vighnesh Dobale expressed enthusiasm about bringing HeartEase to Android users, emphasizing the company's broader vision of making AI healthcare solutions accessible across multiple platforms. "This is just the first step in our journey," he stated, indicating the company's commitment to ongoing innovation in the health tech space.
NeuralBase AI Ltd. operates under the BMP AI brand, which focuses on developing secure, conversational systems and workflow automation to enhance productivity while ensuring data security. The company is currently in the beta testing phase of its BMP AI platform, which aims to improve internal operations and collaboration within enterprises.
Alongside the announcement, NeuralBase provided a legal disclaimer regarding forward-looking statements, outlining potential risks and uncertainties that could affect the company's projections. The company is a fully reporting entity with the U.S. SEC, and its financial filings are accessible via the SEC’s EDGAR database.
Investors interested in NeuralBase AI Ltd. should conduct thorough due diligence and consider the inherent risks associated with trading on the OTC Markets. Additional information about the company can be found on its official website and through SEC resources.
MWN-AI** Analysis
As NeuralBase AI Ltd. (OTC: NBBI) advances towards launching its HeartEase mobile application on the Google Play Store, investors should consider the implications of this milestone for their investment strategy. The HeartEase app aims to provide users with AI-driven insights into heart health, potentially positioning NeuralBase at the forefront of the rapidly expanding digital health market.
With a growing awareness of heart health and the general trend towards personalized healthcare solutions, the timing of the HeartEase launch appears favorable. Investors should note that, upon successful deployment, the app will not only enhance NeuralBase's visibility but could also stimulate user engagement and revenue growth. The company plans to follow up the Android release with an iOS version, thus broadening its customer base even further.
Given the nature of this innovative technology, there exists a significant market opportunity. The digital wellness segment is projected to expand significantly, fueled by both consumer demand for health management tools and advancements in AI technology. NeuralBase's emphasis on compliance and security further enhances its appeal, particularly for enterprise clients seeking reliable solutions.
However, potential investors must remain cautious. NeuralBase is traded on the OTC Markets, which historically exhibit lower liquidity and higher volatility compared to larger exchanges, making shares more susceptible to price swings. Moreover, the realization of projected outcomes surrounding the HeartEase launch and the broader BMP AI platform relies heavily on successful product performance and market acceptance.
In summary, while the upcoming app launch presents a compelling opportunity for NeuralBase, thorough due diligence is essential. Investors should closely monitor the app's reception, user acquisition metrics, and overall market dynamics to gauge the potential for long-term growth in their portfolio. Consulting with financial advisors is recommended to navigate the complexities of investing in emerging technologies within volatile markets.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, NV - August 12, 2025 (NEWMEDIAWIRE) - NeuralBase AI Ltd. (OTC: NBBI), operating under its enterprise brand BMP AI, is pleased to announce that the company has officially submitted its innovative HeartEase mobile application for review on the Google Play Store. This milestone marks a major step toward making HeartEase available to Android users worldwide.
The HeartEase app is designed to deliver advanced, AI-powered health and wellness support, empowering users with real-time insights and personalized guidance for heart health.
Following the Android release, the company will immediately proceed with final testing and submission of the iOS version to the Apple App Store, ensuring HeartEase is accessible to a broad global audience.
"We are thrilled to bring HeartEase to the Android community and look forward to its imminent launch. This is just the first step in our broader vision to make AI-driven healthcare support available to everyone, on every platform," stated Vighnesh Dobale, CEO of NeuralBase AI.
Once the review process by Google Play is complete and the app is published, NeuralBase will provide an additional update.
Additional information about NeuralBase AI Ltd. is available at https://www.neuralbase.ai or by visiting https://www.sec.gov.
About NEURALBASE AI LTD.
NeuralBase AI Ltd. (OTC: NBBI) is a publicly traded AI company focused on secure, scalable, and context-aware conversational systems and workflow automation. Through its BMP AI platform, currently in beta testing, the Company enables enterprises to streamline internal operations, enhance team collaboration, and improve productivity while maintaining compliance and data security.
Legal Disclaimer and Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements reflect current expectations, estimates, and projections of NeuralBase AI Ltd. (the “Company” or “NBBI”) based on assumptions and current market conditions. Forward-looking statements may include terms such as “aims,” “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “could,” “should,” and similar expressions.
These statements relate, among other things, to the expected features and performance of the BMP AI platform; the timing and success of product development; potential industry applications; and overall strategic direction. All forward-looking statements are inherently subject to risks and uncertainties that may cause actual results to differ materially from those projected.
NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC’s EDGAR database at www.sec.gov. The Company trades on the OTC Markets under the ticker symbol NBBI.
This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended.
Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision.
Media Contact:
Vighnesh Dobale
Chief Executive Officer
ir@neuralbase.ai
(727) 314-3717
View the original release on www.newmediawire.com
FAQ**
How does NeuralBase AI Ltd. NBBI plan to leverage the data gathered from the HeartEase app to enhance its AI-driven healthcare capabilities in the future?
What competitive advantages does NeuralBase AI Ltd. NBBI believe HeartEase will have in the rapidly evolving health and wellness app market?
Can NeuralBase AI Ltd. NBBI provide insights into the expected timeline for the iOS version of HeartEase and any unique features it will offer compared to the Android version?
What measures is NeuralBase AI Ltd. NBBI implementing to ensure user data privacy and security within the HeartEase mobile application?
**MWN-AI FAQ is based on asking OpenAI questions about Neuralbase AI Ltd. (OTC: NBBI).
NASDAQ: NBBI
NBBI Trading
31.99% G/L:
$5.90 Last:
43,348 Volume:
$6 Open:
